This issue of Hematology/Oncology Clinics, guest edited by Dr. Caron A. Jacobson, with consulting editors George P. Canellos and H. Franklin Bunn, will focus on Non-Hodgkin’s Lymphoma. Topics include, but are not limited to: Ontogeny, Genetics, Molecular Biology and Classification of B and T cell Non-Hodgkin’s Lymphoma; Diffuse large B cell lymphoma and high grade B cell lymphoma; Burkitt lymphoma and other highly aggressive B cell lymphomas; CNS lymphoma; Mantle cell lymphoma; Follicular lymphoma; Marginal zone lymphoma and lymphoplasmacytic lymphoma; Non-cutaneous T cell lymphoma; Cutaneous T cell lymphoma; Transplant and other adoptive immune cell therapies for non-Hodgkin lymphoma; Non-cellular immune therapies for non-Hodgkin’s lymphoma; and Targeting biology in non-Hodgkin’s lymphoma.

This issue of Hematology/Oncology Clinics, guest edited by Dr. Caron A. Jacobson, with consulting editors George P. Canellos and H. Franklin Bunn, will focus on Non-Hodgkin's Lymphoma. Topics include, but are not limited to: Ontogeny, Genetics, Molecular Biology and Classification of B and T cell Non-Hodgkin's Lymphoma; Diffuse large B cell lymphoma and high grade B cell lymphoma; Burkitt lymphoma and other highly aggressive B cell lymphomas; CNS lymphoma; Mantle cell lymphoma; Follicular lymphoma; Marginal zone lymphoma and lymphoplasmacytic lymphoma; Non-cutaneous T cell lymphoma; Cutaneous T cell lymphoma; Transplant and other adoptive immune cell therapies for non-Hodgkin lymphoma; Non-cellular immune therapies for non-Hodgkin's lymphoma; and Targeting biology in non-Hodgkin's lymphoma.

Genetic alterations in cancer, in addition to being the fundamental drivers of tumorigenesis, can give rise to a variety of metabolic adaptations that allow cancer cells to survive and proliferate in diverse tumor microenvironments. This metabolic flexibility is different from normal cellular metabolic processes and leads to heterogeneity in cancer metabolism within the same cancer type or even within the same tumor. In this book, we delve into the complexity and diversity of cancer metabolism, and highlight how understanding the heterogeneity of cancer metabolism is fundamental to the development of effective metabolism-based therapeutic strategies. Deciphering how cancer cells utilize various nutrient resources will enable clinicians and researchers to pair specific chemotherapeutic agents with patients who are most likely to respond with positive outcomes, allowing for more cost-effective and personalized cancer therapeutic strategies.

This issue of Hematology/Oncology Clinics of North America, guest edited by Drs. Bipin Savani and Mohamad Mohty, is devoted to Bone Marrow Transplantation. Articles in this issue include: Acute Myeloid Leukemia (AML); Acute Lymphoid Leukemia (ALL); Myelodysplastic Syndrome (AML); Myeloproliferative disorders (MPD); Chronic Lymphoid Leukemia; Chronic Myeloid Leukemia (CML); Multiple Myeloma and Amyloidosis; Non-Hodgkin Lymphoma (NHL); Hodgkin Lymphoma (HL); Severe Aplastic Anemia (SAA) and Paroxysmal Nocturnal Hemoglobinuria (PNH); Sickle Cell Anemia; Thalassemia; Benign immunodeficiency diseases; and Referral to transplant centers.

This issue of Hematology/Oncology Clinics, Guest Edited by Dr. John P. Leonard, is devoted to Mantle Cell Lymphoma. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Topics discussed in this important issue include: Molecular pathogenesis of Mantle Cell Lymphoma; MCL and cell cycle dysregulation; Heterogeneity in MCL biology and outcomes; Watch and wait in mantle cell lymphoma; Limited stage mantle cell lymphoma; Initial and consolidation therapy for younger patients with MCL; Approach to the initial treatment of older patients with MCL; Current and future approaches to the use of minimal residual disease monitoring in the treatment of patients with MCL; Bruton’s Tyrosine Kinase inhibitors for treatment of Mantle Cell Lymphoma; BTKi resistance in MCL; Blastoid MCL; Allogeneic transplant and CAR-T cell therapy in MCL; Quality of life considerations and chronic therapy in management of patients with MCL; and Key clinical and translational research questions.

This issue of Hematology/Oncology Clinics, Guest Edited by Dr. Jonathan W. Friedberg, is devoted to Follicular Lymphoma. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Articles in this important issue include: Epidemiology of Follicular Lymphoma, Pathogenesis of Follicular Lymphoma, Circulating tumor DNA and MRD assessment in Follicular Lymphoma, Clinical and biological prognostic factors in Follicular Lymphoma, Vitamin D and Follicular Lymphoma, Initial Treatment of Early Stage and Low Tumor Burden Follicular Lymphoma, Initial Treatment of High Tumor Burden Follicular Lymphoma, Maintenance Antibody Therapy of Follicular Lymphoma, Cellular Therapy in Follicular Lymphoma, Immunomodulatory Agents in Follicular Lymphoma, Phosphoinositide 3-Kinase Inhibition in Follicular Lymphoma, Novel Agents Beyond Immunomodulatory Imide Drugs and Phosphoinositide 3-Kinases for Follicular Lymphoma, Early progression of Follicular Lymphoma, Biological Basis of Histological Transformation, and Treatment of Histological Transformation.

In this issue of Hematology/Oncology Clinics, guest editors Drs. Sarah B. Goldberg and Roy S. Herbst bring their considerable expertise to the topic of Lung Cancer. Top experts in the field cover key topics such as state-of-the-art pathologic and molecular testing; neoadjuvant vs. adjuvant therapy for early-stage NSCLC; new therapies on the horizon (immunotherapy, ADCs, etc.); supportive care and symptom management; smoking cessation; and more. Contains 15 relevant, practice-oriented topics including lung cancer screening; advances in surgical techniques for lung cancer; non-surgical therapy for early-stage lung cancer; locally advanced lung cancer; what’s new in small cell lung cancer; and more. Provides in-depth clinical reviews on lung cancer, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

This issue of Hematology/Oncology Clinics, guest edited by Patrick A. Ott, will focus on Immunotherapy in Cancer. Topics include, but are not limited to, Cancer Vaccines, Innate Immune stimulation, Costimulatory and Agonistic Antibodies, Immune modulation with radiation, Oncolytic virus therapy, Cytokine Therapy, Adoptive T cell transfer, Immune related toxicity, and Immune checkpoint combinations.

This issue of Hematology/Oncology Clinics, guest edited by Dr. Jennifer R. Brown?, will focus on Chronic Lymphocytic Leukemia. This issue is one of six selected each year by our series consulting editors, Dr. George P. Canellos and Dr. Edward J. Benz. Topics discussed in this issue will include: Chronic Lymphocytic Leukemia: Do We Know the Cell of Origin Yet?; Significance of BCR Stereotypy; Prognostic and Predictive Implications of Cytogenetics and Genomics; Role of Epigenetics in Chronic Lymphocytic Leukemia; Genomics of Resistance to Targeted Therapies; First Line Therapy for Chronic Lymphocytic Leukemia; The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia Therapy; BTK Inhibitors; Minimal Residual Disease; Should Undetectable MRD Be the Goal of Chronic Lymphocytic Leukemia Therapy?; Management of Chronic Lymphocytic Leukemia after Progression on BTK Inhibitors; Role of PI3K Inhibitors in Chronic Lymphocytic Leukemia; Can We Restore the Immunodeficiency of Chronic Lymphocytic Leukemia?; and Immune Therapy for Chronic Lymphocytic Leukemia

In this issue of Hematology/Oncology Clinics, guest editors Drs. Jorge J. Castillo, Prashant Kapoor, and Shayna Sarosiek bring their considerable expertise to the topic of Waldenström Macroglobulinemia. Top experts in the field provide a focused update on the biology, diagnosis and management, and novel therapies for patients with Waldenström macroglobulinemia, a rare blood cell cancer characterized by an excess of abnormal white blood cells in the bone marrow. - Contains 14 practice-oriented topics including clinical implications of genomic profile in Waldenström macroglobulinemia; chemoimmunotherapy regimens in the frontline management of Waldenström macroglobulinemia; management of relapsed or refractory Waldenström macroglobulinemia; evaluation and management of aggressive transformation in Waldenström macroglobulinemia; management of Waldenström macroglobulinemia in limited-resource settings; and more. - Provides in-depth clinical reviews of Waldenström macroglobulinemia, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.